FilingSEC EDGAR6-K
ProQR Therapeutics Completes First Dosing in Phase 1 Study of AX-0811
· SEC accepted
StagePhase 1
Filing content
ProQR Therapeutics announced that the first participant has been dosed in the Phase 1 clinical trial of AX-0811, with initial target engagement data expected in early January 2027.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…